The aim of this study was to compare the efficacy of ciclesonide (80 mg/day) and fluticasone propionate (200 mg/day) for mild to moderate persistent asthma. Materials and Methods: Female and male patients older than 12 years with a history of persistent bronchial asthma for at least 6 months were enrolled. Patients were eligible to enter into a 2-week run-in period before randomization (baseline) if they had received inhaled corticosteroids (fluticasone propionate 250 µg/day or equivalent) at a constant dose during the last 4 weeks before the run-in period. In order to enter into the double blind 18-week treatment period, patients had to have a forced expiratory volume in 1s (FEV 1 ) of 61-90% of predicted and a decrease in FEV 1 throughout the run-in period of more than 10%. Patients (n =230) were assigned to ciclesonide 80 mg once daily or fluticasone propionate 100 mg twice daily group. The primary outcome variable was change in FEV 1 compared to its baseline value. Secondary outcome variables were asthma-specific quality of life and asthma control. Results: Both drugs significantly increased FEV 1 and other lung function parameters compared to baseline (P< 0.0001, both groups, all variables). Progress in the percentage of days with no asthma symptoms and no use of rescue medication and asthma-specific quality of life were similar in the two treatment groups. Conclusion: Ciclesonide at a dose of 80 µg once daily can provide efficient maintenance therapy for mild to moderate persistent asthma.
INTRODUCTION
Bronchial asthma is one of the most prevalent chronic diseases worldwide and is responsible for 1% of the entire annual global burden of disease (1) . Although, there is no cure for asthma, pharmacotherapy can relief acute symptoms of the disease or reduce the underlying inflammatory processes in order to achieve effective asthma control. At present inhaled corticosteroids are the most commonly used anti-inflammatory drugs in asthma control and according to national and international guidelines, they are recommended as the first-line agents for persistent asthma, either alone or combined with longacting beta-agonists (2, 3) . Ciclesonide is a glucocorticosteroid-ester pro-drug, presently approved for persistent asthma control in many countries worldwide. It is produced in the form of a solution for inhalation by means of a pressurized metered-dose inhaler (MDI) with hydrofluoroalkane (HFA) 134a as a propellant. Efficacy of ciclesonide has been shown in some placebo-controlled
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Tanaffos 2015; 14 (1) : [1] [2] [3] [4] [5] [6] [7] [8] [9] comparative trials in children and adults (4, 5) . In Europe, the preferred starting dose of ciclesonide in adults is 160 µg once daily. A lower dose of ciclesonide, 80 µg once daily, considerably improved lung function markers in comparison with placebo in patients with mild to moderate persistent asthma in two 12-week trials (6, 7) . In addition, ciclesonide 80 µg once daily attenuated the early and late asthmatic reactions after allergen challenge and notably reduced exercise-induced bronchoconstriction after one week of therapy (8, 9) . A comparative 12-week study in patients with persistent asthma (older than 12 years) demonstrated similar asthma control efficacy of two doses of ciclesonide, 80 µg and 160 µg once daily, and fluticasone propionate 100 µg twice daily (10) .
The aim of the present study was to confirm the longterm efficacy of ciclesonide 80 µg once daily during 18 weeks in patients with mild persistent asthma. For this reason, ciclesonide was compared with fluticasone propionate 100 µg twice daily.
MATERIALS AND METHODS

Patients
Female and male patients older than 12 years with a history of persistent bronchial asthma (11) weeks (or termination of the study) and answered to each question using a 7-point scale from 1 (maximal destruction) to 7 (no destruction). The net benefit in quality of life was measured as the proportion of patients with an increase of at least 0.5 in the total AQLQ(S) score (improvement) minus the proportion of patients with a decrease of at least 0.5 in total AQLQ(S) score (deterioration).
Tolerability and safety assessments
Adverse events (AEs) were recorded at every trial visit.
The researcher defined the severity of AE as mild, moderate, or severe and evaluated the causal association between the AE and use of study drug. The patients'
oropharynx was examined at each visit and a swab test was carried out if oral candidiasis was suspected. Vital sign items (blood pressure, heart rate) and physical examinations were conducted at the start of the run-in period and after 18 weeks of treatment (or at the time of premature discontinuation).
Statistical analysis
Efficacy variables were analyzed according to an 
RESULTS
Study population
Of the 300 patients who enrolled in the run-in phase, 230 were assigned to one of the two treatment groups (ITT:
ciclesonide 80 µg once daily, n =115; fluticasone propionate 100 µg twice daily, n =115). In total, 215 patients completed the study, 110 patients in the ciclesonide group and 105 patients in the fluticasone propionate groups (Figure 1 ).
The main reason for premature trial discontinuation was patient's request or unwillingness to continue. All randomized patients received as a minimum one dose of study drug and were enrolled in the ITT and safety measurements. Except for smoking status (relatively more never-smokers were found in the ciclesonide group than in the fluticasone propionate group), the baseline characteristics were similar in both treatment groups ( classification. According to the diary entries, the median acquiescence to study drug was 99% (range 99-100%) in the two treatment groups. (Table 2 ). Non-inferiority of ciclesonide 80 µg once daily to fluticasone propionate 100 µg twice daily was displayed for change in FEV 1 from baseline to the end of the treatment phase (PP and ITT analyses; Table   2 ). FVC as the secondary lung function variable significantly improved from baseline in the fluticasone propionate group and in the ciclesonide group (P < 0.0001, both groups, all post-baseline visits, PP and ITT analyses; Table 2 ). Non-inferiority of ciclesonide 80 µg once daily to fluticasone propionate 100 µg twice daily was confirmed for the changes in FVC from baseline to the end of the treatment period in both the PP and ITT analyses ( Table 2 ). 
Lung function
Quality of life
Asthma-specific quality of life improved considerably from baseline in two treatment groups with regard to AQLQ (S) overall score ( Table 2) . Non-inferiority of ciclesonide 80 µg once daily to fluticasone propionate 100 µg twice daily was demonstrated for the change from baseline to the end of the treatment phase in the AQLQ(S) overall score and all individual domain scores (P < 0.0001, one-sided, all scores, PP and ITT analyses).
Tolerability and safety
The incidence of treatment-emergent adverse events (6, 7, 13) . A randomized, doubleblind survey in patients older than 12 years with mild to moderate persistent asthma showed that ciclesonide 160 µg once daily and fluticasone propionate 100 µg twice daily were similar in both improving lung function and reducing asthma symptoms and rescue drug use (14) . HFA based, fine particle formulations like ciclesonide are largely deposited in the peripheral regions of the lung (15, 16) .
They seem to be more effective in controlling eosinophilic inflammation in the small airways than more conventional formulations with larger particle sizes (17) (18) (19) . Optimal delivery to all parts of the lung may have special importance when using reduced corticosteroid doses. To were comparatively high in both groups. However, both treatments caused statistically significant improvements in the AQLQ(S) overall score. The incidence of adverse events during the 18-week trial period was low and similar in both groups. Relatively higher number of associated adverse events, which were mainly local reactions such as oral candidiasis, was detected in fluticasone propionate group than in the ciclesonide group. This is not unexpected, because the daily dose of fluticasone propionate was twice as high as that of ciclesonide.
Nevertheless, the incidence of local oropharyngeal adverse events reported in previous trials evaluating comparable doses of the two inhaled corticosteroids also designated better local tolerability of ciclesonide (32, 33) . Inhaled corticosteroids commonly result in minimal side effects at low to moderate doses. On the other hand, non-compliance is a trouble in long-term asthma management and patients who experience adverse effects are more likely to discontinue their drugs than patients who do not (34) .
CONCLUSION
This 18-week study confirmed similar efficacy of fluticasone propionate 100 µg twice daily and ciclesonide 80 µg once daily in patients with mild to moderate persistent asthma and showed that low-dose ciclesonide was efficient for long-term treatments. According to these findings, it can be concluded that ciclesonide at a dose of 80 µg once daily can provide efficient maintenance therapy for mild to moderate persistent asthma.
